Brindisi Giulia, Gori Alessandra, Anania Caterina, Martinelli Ivana, Capponi Martina, De Castro Giovanna, Zicari Anna Maria
Department of Mother-Child, Urological Science, Sapienza University of Rome, 00161 Rome, Italy.
Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.
J Clin Med. 2023 Jun 27;12(13):4327. doi: 10.3390/jcm12134327.
We followed the effects of a new SCIT with a chemically polymerized allergen Alt a1, evaluating the trend of clinical and functional parameters in an observational-prospective study.
42 children with AR and intermittent asthma sensitized to A.A.: 17 patients started SCIT (Modigoid), and 25 continued symptomatic therapy. At the initial visit (T0), all patients performed total IgE (tIgE) and specific IgE (sIgE) for Alt a1, nasal nitric oxide (nFeNo), nasal cytology, anterior active rhinomanometry (AAR) and spirometry. After 24 months (T1), they repeated the same procedures as in T0.
Patients treated with Modigoid presented a statistically significant ( < 0.001) reduction of nFeNO (T0:1651.06 ± 149.18; T1: 1394.12 ± 108.98), tIgE (T0: 311.48 ± 144.18; T1: 164.73 ± 50.69), sIgE for Alt a1 (T0: 28.59 ± 12.69; T1: 19.54 ± 7.37), an improvement of nasal airflow (T0: 71.62 ± 8.66; T1: 95.12 ± 5.91), nasal eosinophils (T0: 20.59 ± 2.35; T1: 14.88 ± 1.65) and FEV1 (T0: 95.58 ± 7.91; T1: 116.64 ± 5.94).
The new SCIT for Alt a1 significantly improves AR symptoms from a subjective, objective point of view and laboratory and functional parameters.
我们追踪了一种使用化学聚合变应原Alt a1进行的新型皮下免疫疗法（SCIT）的效果，在一项观察性前瞻性研究中评估临床和功能参数的变化趋势。
42名对A.A.过敏的变应性鼻炎（AR）和间歇性哮喘患儿：17名患者开始接受皮下免疫疗法（Modigoid），25名继续进行对症治疗。在初次就诊时（T0），所有患者均检测了总IgE（tIgE）、针对Alt a1的特异性IgE（sIgE）、鼻一氧化氮（nFeNo）、鼻细胞学检查、前鼻主动测压法（AAR）和肺量计检查。24个月后（T1），他们重复了与T0相同的检查项目。
接受Modigoid治疗的患者，其nFeNO（T0：1651.06±149.18；T1：1394.12±108.98）、tIgE（T0：311.48±144.18；T1：164.73±50.69）、针对Alt a1的sIgE（T0：28.59±12.69；T1：19.54±7.37）有统计学意义的显著降低（<0.001），鼻气流（T0：71.62±8.66；T1：95.12±5.91）、鼻嗜酸性粒细胞（T0：20.59±2.35；T1：14.88±1.65）和第一秒用力呼气容积（FEV1）（T0：95.58±7.91；T1：116.64±5.94）有所改善。
新型针对Alt a1的皮下免疫疗法从主观、客观角度以及实验室和功能参数方面均显著改善了变应性鼻炎症状。
